Drug Trial Radar · NCT07097701
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Sep 3, 2025
Primary completion
Jan 22, 2027
Study completion Feb 22, 2027
Sponsor
- Lead sponsor
- Lupin Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Lupin Atlantis Holdings S.A.
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)
Conditions
- Myotonia
Interventions
Granular powder in unit dose foil-lined sachet Mexiletine (PR)Drug
Mexiletine (PR)
Oral Capsule Mexiletine (IR)Drug
Mexiletine (IR)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the safety of mexiletine PR vs mexiletine IR by incidence of treatment emergent Adverse Events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate between mexiletine PR and mexiletine IR after 12 weeks of treatment.Time frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QTc intervals by12-lead in ECGTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in PR intervals by12-lead in ECGTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QRS intervals by12-lead in ECGTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline by average minimum heart rate by12-lead in ECGTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by performing physical examiniationsTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by assessing vital signsTime frame: Baseline to week 24
- To compare the safety of mexiletine PR vs mexiletine IR by performing standard clinical laboratory evaluationsTime frame: Baseline to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Universitair Ziekenhuis Leuven"UZ Leuven Gasthuisberg Campus Herestraat 49 Leuven, 3000"
Leuven, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.